Department of Dermatology and Venereology, Rare Diseases Center, West China Hospital, Sichuan University, Chengdu, Sichuan, People's Republic of China.
Dermatol Ther. 2022 Oct;35(10):e15754. doi: 10.1111/dth.15754. Epub 2022 Aug 12.
We report a case of aggressive bullous pemphigoid (BP) concurrent with plaque psoriasis successfully treated with Janus kinase inhibitor Baricitinib. The 83-year-old Chinese man suffered 10 years of psoriasis and developed BP with typical intense blisters and significantly elevated serum anti-BP180 autoantibodies. Due to concerns on his poor health conditions including stage III hypertension and potential serious side effects of standard treatment with systematic steroid, he was given Baricitinib orally 4 mg/day. Significant improvement in skin lesions and pruritus was noted following treatment for 12 weeks, from which the dose of Baricitinib was halved and continued for an additional 12 weeks. He showed a complete remission of both bullous and psoriatic lesions without any adverse effects at the 24-week follow-up visit. Our observation suggests a potential of Baricitinib as a new alternative therapeutic option for concurrent plaque psoriasis and BP or either of them.
我们报告了一例并发斑块状银屑病的侵袭性大疱性类天疱疮（BP）患者，成功使用 Janus 激酶抑制剂巴瑞替尼进行了治疗。这位 83 岁的中国男性患有 10 年的银屑病，并出现了具有典型剧烈水疱和明显升高的血清抗 BP180 自身抗体的 BP。由于担心他的健康状况不佳，包括 III 期高血压和标准治疗系统性类固醇的潜在严重副作用，他每天口服 4 毫克巴瑞替尼。治疗 12 周后，皮肤病变和瘙痒明显改善，随后将巴瑞替尼的剂量减半，并继续治疗 12 周。在 24 周随访时，他的大疱和银屑病皮损完全缓解，没有任何不良反应。我们的观察结果表明，巴瑞替尼可能成为并发斑块状银屑病和 BP 或其中任何一种疾病的新的治疗选择。
